I-Mab is pursuing mRNA therapies, eyeing orally delivered antibodies for ‘third wave’ of its immuno-oncology pipeline

mRNA therapeutics and orally delivered antibodies are next on the docket as I-Mab continues to build out the next generation of its immuno-oncology portfolio.

“I-Mab’s innovation comes in three waves,” Chairman and Director Jingwu Zang told BioCentury ahead of the company’s R&D day Monday. The first consisted of mAbs, followed by a second wave focused on bispecific antibodies. ...